CN1302795C - Drug-dropping medicine and its preparing method - Google Patents
Drug-dropping medicine and its preparing method Download PDFInfo
- Publication number
- CN1302795C CN1302795C CNB2004100003612A CN200410000361A CN1302795C CN 1302795 C CN1302795 C CN 1302795C CN B2004100003612 A CNB2004100003612 A CN B2004100003612A CN 200410000361 A CN200410000361 A CN 200410000361A CN 1302795 C CN1302795 C CN 1302795C
- Authority
- CN
- China
- Prior art keywords
- weight
- radix
- crude drug
- medicine
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims description 5
- 229940079593 drug Drugs 0.000 claims abstract description 36
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 22
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 241000208340 Araliaceae Species 0.000 claims abstract description 6
- 239000009636 Huang Qi Substances 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000009286 sanguis draxonis Substances 0.000 claims description 9
- 239000011265 semifinished product Substances 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 238000001256 steam distillation Methods 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000006870 function Effects 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 4
- 231100000765 toxin Toxicity 0.000 abstract description 4
- 235000006533 astragalus Nutrition 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract 1
- 235000017491 Bambusa tulda Nutrition 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract 1
- 239000011425 bamboo Substances 0.000 abstract 1
- 239000009136 dragon's blood Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 description 19
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 10
- 208000004880 Polyuria Diseases 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000035619 diuresis Effects 0.000 description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 6
- 208000011117 substance-related disease Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010013654 Drug abuse Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 240000008058 Lilium brownii Species 0.000 description 1
- 235000015982 Lilium brownii Nutrition 0.000 description 1
- 244000003342 Lilium longiflorum Species 0.000 description 1
- 235000005356 Lilium longiflorum Nutrition 0.000 description 1
- 241001359444 Lilium tenuifolium Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 240000005827 Phyllostachys nigra Species 0.000 description 1
- 235000010717 Phyllostachys nigra Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 241001474728 Satyrodes eurydice Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- -1 add entry Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- WTYGAUXICFETTC-UHFFFAOYSA-N cyclobarbital Chemical compound C=1CCCCC=1C1(CC)C(=O)NC(=O)NC1=O WTYGAUXICFETTC-UHFFFAOYSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 244000186071 dragons blood palm Species 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960002532 methamphetamine hydrochloride Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a drug abstinence medicine which is prepared from ginseng, coptis, cassia bark, milkvetch root, lily bulb, panax notoginseng, dragon blood, dens draconis and bamboo leaf according to a certain weight percentage. The drug abstinence medicine of the present invention can be made into any common oral administration preparation, and has the functions of regulation of yin and yang, restoring the normal coordination between the heart and the kidney, consolidating the constitution, detoxifying and expelling the toxin. The drug abstinence medicine of the present invention has preeminent curative effect on a series of abstinence syndromes during the drug abstinence.
Description
Technical field
The invention belongs to the field of Chinese medicines, relate to a kind of anti-additive medicament and preparation method thereof.
Background technology
According to World Health Organization (WHO) statistics, it is about 100,000 that the number of drug abuse is died from the whole world every year, has 1,000 ten thousand because of normal intelligence of forfeiture and the ability to work of taking drugs.China Ministry of Public Security statistics shows that drug abuse also constantly spreads and in rising trend in China, and China in 1999 number of taking drugs that registers on the books is 680,000, increases people more than 8.5 ten thousand than 1998, rises 14.3%.Therefore, must prevent and treat energetically.
At present, the herbal species that is used to quit drug abuse has FUKANG PIAN, clever beneficial capsule, peace oral liquid, a Jinan-Tai'an sheet, sets upright health electuary, the peaceful micropill of peace monarch, glad, the profound summer withdrawal of rehabilitation capsule etc.These pharmaceutical formulations are formed different, are having their own characteristics each aspect the control withdrawal symptom.Have to watery nasal discharge, shed tears, symptom such as hyperhidrosis has control action preferably, the pain management preferably that has, gastrointestinal symptoms such as can solving preferably of having is nauseating, vomiting are better.But the comprehensive therapeutic effect of these medicines is not good, and reverts to take drugs easily after the drug withdrawal.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine of quitting drug abuse of more being effective to.
Another object of the present invention has provided this preparation method of Chinese medicine.
This product is to hand over safe ball side, and Dens Draconis, Bulbus Lilii etc. are handed over Ji extreme misery; The Radix Ginseng QI invigorating is kept and is not walked, and mends congenital gas, and Radix Astragali QI invigorating is walked and do not kept, and mends the gas of the day after tomorrow, the merit of playing vital base and primordial QI consolidating altogether, Radix Notoginseng, Sanguis Draxonis promoting blood circulation, dredging meridian and relieving pain; The detoxifcation of Herba Lophatheri clearing away heat and promoting diuresis, all medicines cooperate can give up drug addiction rapidly.
The consumption of drug component of the present invention is groped to sum up to draw through the inventor in a large number, and each amounts of components all has better curative effect at following content range (weight %):
Radix Ginseng 7.5～8.8% Cortex Cinnamomis 1～4% Bulbus Lilii 20～27% Sanguis Draxonis 0.55～0.65% Folium Bambusae 7～12% Rhizoma Coptidis 1～2.6% Radix Astragali 21～24% Radix Notoginsengs 7～12% Dens Draconiss 18～26%.
The preferable content range of each drug component is Radix Ginseng 7.8～8.4% Cortex Cinnamomis 1～2.5% Bulbus Lilii 22～25% Sanguis Draxonis 0.55～0.65% Folium Bambusae 8.5～11% Rhizoma Coptidis 1～2% Radix Astragali 22～23.5% Radix Notoginsengs 8～10% Dens Draconiss 22.2～24%.
The optimum content scope is Radix Ginseng 8.3% Cortex Cinnamomi 1.31% Bulbus Lilii 24.6% Sanguis Draxonis 0.62% Folium Bambusae 8.4% Rhizoma Coptidis 1.25% Radix Astragali 23.1% Radix Notoginseng 8.5% Dens Draconis 23.92%.
Radix Ginseng described in the present invention (Panax ginseng C.A.Mey) is the root of Araliaceae Radix Ginseng, place of production Korea S.
Rhizoma Coptidis described in the present invention (Coptis chinensis Franch) is a perennial herb Rhizoma Coptidis rhizome, gets wildly, and the place of production is Sichuan Province.
Cortex Cinnamomi described in the present invention (Cinnamomum cassia Presl) strips bark for aiphyllium in 8～10, and it is wild to get Vietnam.
The Radix Astragali described in the present invention (Astragalus membranaceus Bge) is the dry root of the leguminous plant Radix Astragali, real estate Hebei.
Bulbus Lilii described in the present invention (Lilium brownii F.E.Brown.var.ColchesteriWILS.) is the liliaceous plant Bulbus Lilii, the scale leaf of Lilium tenuifolium, Lilium longiflorum and congener bulb thereof, and it is several all over the whole nation to distribute.
Dens Draconis described in the present invention for ancient times mammal resemble the tooth fossil of class or rhinoceros class, originate in Shanxi, the Inner Mongol, Shaanxi, Gansu, Hebei, ground such as Hubei and Henan.
Radix Notoginseng described in the present invention (Panax pseudo-ginseng WELL.Var.Notoginseng (burkin) Hoo﹠amp; Tseng) be the root of Araliaceae Panax pseudoginseng, get the wild survivor in Yunnan.
Sanguis Draxonis described in the present invention (DAEMONOROPS DRACO.BC.) is the fruit of babassu Sanguis Draxonis and the resin in the trunk, gets Malaysia and produces.
Herba Lophatheri described in the present invention (Phyllostachys nigra (lodd) Munro.var.Henonis stapt ex rendle) is the leaf of many years herbaceous plant Herba Lophatheris of Qiao Benke, main product in the Yangtze river basin to southern each province.
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral formulations.For example can evenly make powder and take after mixing it with water these crude drug pulverizes are mixed, but better bring into play drug effect, preferably, Cortex Cinnamomi is extracted its volatile oil with steam distillation the Radix Ginseng ethanol extraction in this crude drug for each raw material that makes this medicine.But these can not be used to limit protection scope of the present invention.
The preparation method of preferred medicine activity component of the present invention is as follows:
A) take by weighing crude drug Rhizoma Coptidis, the Radix Astragali, Bulbus Lilii, the Radix Notoginseng of described weight percentage, be ground into powder, add entry, extract being lower than 40 ℃ of following mercerations, filter then,, make extractum being lower than 40 ℃ of following concentrated filtrates.
B) take by weighing crude drug Dens Draconis, the Folium Bambusae of described weight percentage, pulverize and mix.
C) take by weighing the crude drug Cortex Cinnamomi of described weight percentage, with steam distillation reflux, extract, effective ingredient, extract.
D) take by weighing the crude drug Radix Ginseng of described weight percentage, pulverize, extract being lower than 40 ℃ of following mercerations, filter,, make extractum being lower than 40 ℃ of following concentrated filtrates with 70～80% ethanol.
E) with step a), c), d) extractum that obtains and extract mix, and use b) powder and the starch absorption mixed liquor that obtain, then mixed liquor is placed baking oven, 10～40 ℃ dry down, pulverize then, semi-finished product are made in mixing.
The amount that wherein adds starch is 3～5 weight % of crude drug total amount.
The active component of medicine of the present invention can add various conventional adjuvant required when preparing different dosage form, be prepared into any peroral dosage form commonly used as disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine, as pill, powder, tablet, capsule, oral liquid etc.
Medicine of the present invention has the effect of regulating YIN and YANG, restoring normal coordination between the heart and kidney, vital base and primordial QI consolidating, detoxication and toxicant eliminating function, the withdrawal syndrome that the drug rehabilitation of energy better controlled causes, the opiates toxin can be excreted by body fluid, reach the purpose that purifies health, removes heart addiction, quits drug abuse fast, thereby the comprehensive therapeutic effect of detoxification is good, cures short treating period and difficult reverting to take drugs.
Obtain on the basis of promising result at prolonged application this product decoct, the crude drug of Chinese medicine of the present invention has been carried out modern pharmacological research, result of study is as follows:
1. antagonism drugs effect: Radix Ginseng energy facedown morphine, ethanol, inhibited to the trained reflex of dependence producing drug.
2. calm, analgesic activity: Rhizoma Coptidis has the effect of the length of one's sleep of local anesthesia, calmness, analgesia, prolongation pentobarbital.Cinnamic aldehyde in the Cortex Cinnamomi has tangible sedation to mice, and it shows as, and spontaneous activity reduces, the antagonism movement disorder of crossing multi-activity, transfer rod experiment generation that methamphetamine produced improves, prolongs the anesthesia duration of ciclobarbital soluble.Use mice and press anal spine to swash or lumbar injection acetic acid is observed the method proof Cortex Cinnamomi of turning round the body motion analgesic activity is arranged, Cortex Cinnamomi can postpone tonic convulsion and the death time that strychnine causes in addition, reduces the number of times and the dead incidence rate of tonic convulsion.The Radix Astragali: give mouse subcutaneous injection with Radix Astragali injection, find that the Radix Astragali has sedation.Radix Ginseng: heavy dose has sedation, can obviously suppress the spontaneous activity of mice, the convulsions that some central stimulant of antagonism causes, and the sleep that pentobarbital causes had synergism in time, so have the effect that improves sleep.
3. improve emotion: Radix Ginseng can improve people's emotion.
4. to the anti-acetylcholine effect: the Rhizoma Coptidis of doses can be to anti-acetylcholine.
5. Detoxication: Rhizoma Coptidis can be strengthened the function of detoxification of liver, and can resist the softening sheath that takes off of neural white matter and separate neural poison.
6. toxin expelling effect: Radix Notoginseng can be accelerated circulation, and strong diuresis is arranged, and when dosage reached 75mg/kg, its diuresis can reach more than 5 times of conventional diuresis amount; It is suitable with aminophylline 0.05g/kg and hydrochlorothiazide 0.25mg/kg that the diuresis of Radix Astragali 0.5g/kg is tired, and the diuresis persistent period is longer, successive administration 7 days does not produce drug resistance yet, and healthy human oral astragalus decoction also has diuresis and increases the effect of the discharge of sodium.Herba Lophatheri has diuresis, though it increases a little less than the effect of urine amount, can obviously increase the urine chloride output.Synergism by Radix Notoginseng, the Radix Astragali, Herba Lophatheri is toxin expelling promptly.
7. strong, raising tolerance: Radix Ginseng can significantly improve the animal anti-fatigue ability, participates in VITB12 contrast carrying out decimal swimming test with the people, finds that the swimming time of Radix Ginseng group mice prolongs; Radix Ginseng can increase the defence capability of body to various destructive stimuluses, can prolong the time-to-live of animal, promotes that animal gets well.The Radix Astragali can obviously prolong the swimming time of mice, and weight increase is fast than matched group also.Radix Notoginseng has cardiotonic.
8. antipyretic analgesic effect: Herba Lophatheri has refrigeration function to tentative heating, the antipyretic analgesic effect the when Herba Lophatheri of 10g is equivalent to aspirin one half-value dose.
The specific embodiment
Further set forth medicine of the present invention by the following examples.
The capsule preparation of embodiment 1 medicine of the present invention
A) get Rhizoma Coptidis 1.25g, Radix Astragali 23.1g, Bulbus Lilii 24.6g, Radix Notoginseng 8.5g, be ground into the powder of 24 mesh sieves, add 500ml water, the room temperature merceration extracted 24 hours, filtering then, is concentrating under reduced pressure under 32 ℃ of conditions with filtrate in temperature, is condensed into proportion and is 1.102 extractum 1..
B) Dens Draconis 23.92g, Folium Bambusae 8.4g after 2 hours, pulverize and mix 1000 ℃ of heating with electronics temperature-adjusting type external electronic oven, cross 60 mesh sieves.
C) 2. Cortex Cinnamomi 1.31g gets extract with steam distillation reflux, extract, effective ingredient.
D) Radix Ginseng 8.3g washes, dries through roguing, pulverizes, and crosses 10 mesh sieves, extracts 12 hours with 70% ethanol room temperature merceration, filter, and be concentrating under reduced pressure under 32 ℃ of conditions with filtrate in temperature, be condensed into proportion and be 1.148 extractum 3..
E) will be 1., 2., 3. mix, use b) powder and the 3.5g starch absorption mixed liquor that obtain, then mixed liquor is placed baking oven, the normal pressure freeze-day with constant temperature, temperature is controlled at 35 ℃, pulverizes then, mix, 60 mesh sieves become semi-finished product.
F) semi-finished product that make of the step e) snap fit capsule of packing into, every capsules loading amount is 0.3g, and average loading amount error is ± 10%, and determination of moisture is no more than 6%, is prepared into capsule.
The preparation tablets of embodiment 2 medicines of the present invention
A) get Rhizoma Coptidis 1.7g, Radix Astragali 23g, Bulbus Lilii 26g, Radix Notoginseng 10g, be ground into the powder of 10 mesh sieves, add 600ml water, the room temperature merceration extracted 24 hours, filtering then, is concentrating under reduced pressure under 32 ℃ of conditions with filtrate in temperature, is condensed into proportion and is 1.206 extractum 1..
B) Dens Draconis 19g, Folium Bambusae 11g after 3 hours, pulverize mixing with ball mill 1000 ℃ of heating with electronics temperature-adjusting type external electronic oven, cross 60 mesh sieves.
C) 2. Cortex Cinnamomi 1.1g gets extract with steam distillation reflux, extract, effective ingredient.
D) Radix Ginseng 7.6g washes, dries through roguing, pulverizes, and crosses 30 mesh sieves, extracts 12 hours with 70% ethanol room temperature merceration, filter, and be concentrating under reduced pressure under 40 ℃ of conditions with filtrate in temperature, be condensed into proportion and be 1.320 extractum 3..
E) will be 1., 2., 3. mix, use b) powder and the 5g starch absorption mixed liquor that obtain, then mixed liquor is placed baking oven, the normal pressure freeze-day with constant temperature, temperature is controlled at 40 ℃, pulverizes then, mix, 60 mesh sieves become semi-finished product.
F) semi-finished product that make of step e) add adjuvant and make granule, and compacting in flakes.
The granule preparation of embodiment 3 medicines of the present invention
A) get Rhizoma Coptidis 2.5g, Radix Astragali 21.5g, Bulbus Lilii 21.6g, Radix Notoginseng 7.5g, be ground into the powder of 24 mesh sieves, add 500ml water, the room temperature merceration extracted 24 hours, filtering then, is concentrating under reduced pressure under 32 ℃ of conditions with filtrate in temperature, is condensed into proportion and is 1.108 extractum 1..
B) Dens Draconis 26g, Folium Bambusae 8g after 2 hours, pulverize and mix 1000 ℃ of heating with electronics temperature-adjusting type external electronic oven, cross 60 mesh sieves.
C) 2. Cortex Cinnamomi 3.55g gets extract with steam distillation reflux, extract, effective ingredient.
D) Radix Ginseng 8.8g washes, dries through roguing, pulverizes, and crosses 10 mesh sieves, extracts 12 hours with 70% ethanol room temperature merceration, filter, and be concentrating under reduced pressure under 32 ℃ of conditions with filtrate in temperature, be condensed into proportion and be 1.240 extractum 3..
E) will be 1., 2., 3. mix, use b) powder and the 4g starch absorption mixed liquor that obtain, then mixed liquor is placed baking oven, the normal pressure freeze-day with constant temperature, temperature is controlled at 35 ℃, pulverizes then, mix, 60 mesh sieves become semi-finished product.
F) in the semi-finished product that step e) makes, add ethanol and make binding agent, be pressed into granule.
Test example 1, be example, detect the curative effect of medicine of the present invention with the capsule
1. physical data
Accept out-patient's totally 107 examples for medical treatment, wherein male 51 examples, women 56 examples, the age was 12～30 years old 60 example, 31～50 years old 47 examples have heroin (first-selection), methadone (drink-service when economy does not allow), soft ball son (intermittently taking), Fructus Cannabis (intermittently sucking) through confirming the drugs that these patients inhale clothes.
2. dose
Be grown up each 2, every 4 hours 1 time, can add 2 in the middle of taking medicine in case of necessity every day 4 times at every turn, every day, accumulated dose was no more than 16.Drowsy xerostomias etc. all belong to normal reaction, and disappearing automatically with drug withdrawal need not to handle.
3. diagnosis
The compound addiction of heroin and methadone (is to occur a series of withdrawal symptoms such as agitation, gape, tired, pain, watery nasal discharge after the drug withdrawal.)
4. curative effect judging standard:
Recovery from illness: used this product 7 days, all withdrawal symptoms disappear, and spiritual stomach is received, and have rosy cheeks, weight increase, reverting to take drugs consciousness of nothing, urine morphine test and be negative.
Produce effects: used this product 7 days, all withdrawal symptoms disappear but health is still failed to return to one's perfect health, urinate the morphine test and is negative.
Invalid: as to use this product 7 days, and can not eliminate withdrawal symptom.
5. therapeutic outcome (seeing Table 1)
Table 1 is observation of curative effect after treating
| Treatment time (my god) | Recovery from illness | Produce effects | Invalid | Effective percentage % | |||
| The example number | Cure rate % | The example number | Obvious effective rate % | The example number | Inefficiency % | ||
| 7 | 77 | 72.0 | 25 | 23.4 | 5 | 4.6 | 95.4 |
Therapeutic outcome shows, effective percentage reaches 95.4% in seven days, wherein patient's no pain of 72.0% recovery from illness, the test of urine morphine presents feminine gender, (if any methamphetamine hydrochloride and the compound addict of sleeping pill, treatment needs to prolong 3 days), the physical rehabilitation of spirit, have rosy cheeks, weight increase, immunity, appetite and libido are recovered and are improved.The testing result of its body function is as follows:
Respiratory system: normally do not have following symptom or disease: chronic cough, dyspnea, spitting of blood, low grade fever, robber's juice, chest pain, tracheitis, pneumonia, pulmonary tuberculosis etc.
Blood circulation: medical history such as no cardiopalmus, out of breath, spitting of blood, chest pain, faintness, edema and high and low blood pressure
Digestive system: no hematemesis, have blood in stool, medical history such as jaundice or hepatitis
Genitourinary system: normally do not have medical histories such as lumbago, frequent micturition, hematuria, edema
Endocrine and metabolic system: normal
Nervous system: medical histories such as no headache, dizzy, disturbance of consciousness, tic, paralysis, visual disorder, paraesthesia, personality change, memory and hypophrenia, but intermittent insomnia or drowsiness is arranged.No severe depression, suicide, autosadism or violent tenet, no hallucination, auditory hallucination etc.
Motor system: no swollen joint is painful, the dyskinesia, spasm, tremble, paralysis etc.
This shows that medicine of the present invention has no side effect, use short treating period, instant effect, can control the withdrawal syndrome that drug rehabilitation causes well.
Claims (4)
1. anti-additive medicament is characterized in that it is made by the crude drug of following content range: Radix Ginseng 7.5～8.8 weight %, Cortex Cinnamomi 1～4 weight %, Bulbus Lilii 20～27 weight %, Sanguis Draxonis 0.55～0.65 weight %, Folium Bambusae 7～12 weight %, Rhizoma Coptidis 1～2.6 weight %, the Radix Astragali 21～24 weight %, Radix Notoginseng 7～12 weight %, Dens Draconis 18～26 weight %.
2. the described medicine of claim 1 is characterized in that it is to be made by the crude drug of following content range: Radix Ginseng 7.8～8.4 weight %, Cortex Cinnamomi 1～2.5 weight %, Bulbus Lilii 22～2 weight %, Sanguis Draxonis 0.55～0.6 weight %, Folium Bambusae 8.5～11 weight %, Rhizoma Coptidis 1～2 weight %, the Radix Astragali 22～23.5 weight %, Radix Notoginseng 8～10 weight %, Dens Draconis 22.2～24 weight %.
3. the described medicine of claim 2 is characterized in that it is to be made by the crude drug of following content range: Radix Ginseng 8.3 weight %, Cortex Cinnamomi 1.31 weight %, Bulbus Lilii 24.6 weight %, Sanguis Draxonis 0.62 weight %, Folium Bambusae 8.4 weight %, Rhizoma Coptidis 1.25 weight %, the Radix Astragali 23.1 weight %, Radix Notoginseng 8.5 weight %, Dens Draconis 23.92 weight %.
4. the preparation method of an anti-additive medicament, this method comprises the following steps:
A) provide claim 1 described raw materials by weight percent medicine, take by weighing crude drug Rhizoma Coptidis, the Radix Astragali, Bulbus Lilii, the Radix Notoginseng of described weight percentage, be ground into powder, add entry,, filter then being lower than 40 ℃ of following mercerations extractions, being lower than 40 ℃ of following concentrated filtrates, make extractum.
B) take by weighing crude drug Dens Draconis, the Folium Bambusae of described weight percentage, pulverize and mix.
C) take by weighing the crude drug Cortex Cinnamomi of described weight percentage, with steam distillation reflux, extract, effective ingredient, extract.
D) take by weighing the crude drug Radix Ginseng of described weight percentage, pulverize, extract being lower than 40 ℃ of following mercerations, filter,, make extractum being lower than 40 ℃ of following concentrated filtrates with 70～80% ethanol.
E) with step a), c), d) extractum that obtains and extract mix, and use b) powder and the starch absorption mixed liquor that obtain, then mixed liquor is placed baking oven, 10～40 ℃ dry down, pulverize then, semi-finished product are made in mixing.
F) semi-finished product that make of step e) can be prepared into any peroral dosage form commonly used according to the method for Chinese medicinal of routine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100003612A CN1302795C (en) | 2004-01-09 | 2004-01-09 | Drug-dropping medicine and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100003612A CN1302795C (en) | 2004-01-09 | 2004-01-09 | Drug-dropping medicine and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1640424A CN1640424A (en) | 2005-07-20 |
| CN1302795C true CN1302795C (en) | 2007-03-07 |
Family
ID=34866728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100003612A Expired - Fee Related CN1302795C (en) | 2004-01-09 | 2004-01-09 | Drug-dropping medicine and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1302795C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101417021B (en) * | 2008-11-25 | 2011-03-16 | 张财 | External traditional Chinese medicine for giving up drug habits and preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102344A (en) * | 1994-07-06 | 1995-05-10 | 王兴德 | All-life drug-dropping traditional Chinese medicine |
| CN1260200A (en) * | 1999-08-16 | 2000-07-19 | 万梦雄 | Traditional Chinese medicine compound medicine for giving-up drug-taking and its compounding method |
-
2004
- 2004-01-09 CN CNB2004100003612A patent/CN1302795C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102344A (en) * | 1994-07-06 | 1995-05-10 | 王兴德 | All-life drug-dropping traditional Chinese medicine |
| CN1260200A (en) * | 1999-08-16 | 2000-07-19 | 万梦雄 | Traditional Chinese medicine compound medicine for giving-up drug-taking and its compounding method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1640424A (en) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078473B (en) | Traditional Chinese medicine preparation for treating chronic hepatitis b and preparation method thereof | |
| CN101513437A (en) | Antifatigue Chinese pharmaceutical composition and preparation method thereof | |
| CN1994451B (en) | Chinese medicinal composition for treating depression, its preparation method and application | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN100344313C (en) | Chinese patent drug for treating infantile cold and repeated cold, and its prepn. method | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN102283956A (en) | Orally administered drug for treating chronic hepatitis | |
| CN1302795C (en) | Drug-dropping medicine and its preparing method | |
| CN103191282B (en) | Traditional Chinese medicinal composition for treating fever in children as well as preparation method and application thereof | |
| CN103007159B (en) | Chinese medicinal preparation for correcting pancreas islet function | |
| CN1199679C (en) | Medicine for nourishing yin and fortifying kidney, benefiting qi and fortifying spleen , and its preparation method | |
| CN1586297A (en) | Body building health preparation and its producing method | |
| CN1833703A (en) | Medicine for treating peripheral nervous disease of diabets mellitus and prepn. method | |
| CN105561184A (en) | Medicinal composition for activating blood circulation, dissipating blood stasis, warming meridians and relaxing veins, and preparation method thereof | |
| CN101708230B (en) | Anti-drug medicine and preparation method thereof | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN1518995A (en) | Medication for anti senile dementia as well as preparation method usage | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1244367C (en) | 'Dianjian' liqid for curing epilepsy sickness | |
| CN104306784A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis as well as preparation method and application thereof | |
| CN1310669C (en) | Medicine composition for treating chronic hepatitis and its prepn | |
| CN1463192A (en) | Herb compsns. for treating dopy and agrypnia | |
| CN101041011A (en) | Chinese traditional medicine for preventing and curing AIDS | |
| CN1352966A (en) | Medicine for treating tracheitis and asthma | |
| CN1056308C (en) | Medicine for adjusting cranial nerve function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060317 Address after: 518000 Guangdong city in Shenzhen Province, 100 homestead garden two cloud Xuan 5-7B Applicant after: Hu Xinyuan Co-applicant after: Wang Ximing Co-applicant after: Feng Zhijun Address before: 518000 Guangdong city in Shenzhen Province, 100 homestead garden two cloud Xuan 5-7B Applicant before: Hu Xinyuan Co-applicant before: Wang Ximing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: WANG XIMING FENG ZHIJUN Owner name: SIQI YIJING Free format text: FORMER OWNER: HU XINYUAN Effective date: 20101227 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 518000 5-7B, YUNXUAN, PHASE 2, BAISHIDA GARDEN, SHENZHEN CITY, GUANGDONG PROVINCE TO: 361005 ROOM 105, UNIT 3, BUILDING 1, TIANQUAN FUYI, TIANQUAN XILI, HUANDAO SOUTH ROAD, SIMING DISTRICT, XIAMEN CITY, FUJIAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101227 Address after: 361005 Fujian city of Xiamen province in the West Road around the island Siming Tianquan rich city building No. 1 Tianquan 3 staircase 105 rooms Patentee after: Our Qiyi mirror Address before: 518000 Guangdong city in Shenzhen Province, 100 homestead garden two cloud Xuan 5-7B Co-patentee before: Wang Ximing Patentee before: Hu Xinyuan Co-patentee before: Feng Zhijun |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070307 Termination date: 20160109 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |